Short answer
Inmune Bio, Inc. (INMB) filed an 8-K current report with the SEC on September 14, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Board expanded to seven directors with additions of R. Duane Clark II and James Sapirstein.
Inmune Bio, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Board expanded to seven directors with additions of R. Duane Clark II and James Sapirstein
- Both appointees classified independent under Nasdaq Listing Rule 5605
- Expertise adds rare-disease commercialization, licensing, capital formation and biotechnology transactions
- Each receives options for 100,000 shares, vesting monthly over 36 months
- Each receives $50,000 annual cash retainer plus expense reimbursement
Item 8.01 · Other Events
- Board appointments of Mr. Clark and Mr. Sapirstein announced September 14, 2026
- Governance expansion potentially relevant to strategic oversight and shareholder confidence
- Details of appointees’ backgrounds and roles contained in Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- Board appointments of R. Duane Clark II and James Sapirstein add rare-disease commercialization and biopharma transaction expertise
- Clark’s Sanofi rare-disease leadership supports Ebstrocel™ market access, pricing, patient identification and launch planning
- Sapirstein’s licensing and financing background strengthens potential partnering, co-development and strategic transaction efforts
- CORDStrom™ targets UK MHRA MAA in 2026, EU EMA submission in 2027 and a planned U.S. BLA
- Product candidates remain unapproved, with commercialization dependent on regulatory success and substantial additional funding
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Inmune Bio, Inc. 8-K filings
Get the next INMB 8-K as it lands
Follow INMB for push alerts, or ask the research agent what this filing means.